Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BPI-9016M in advanced solid tumors
NCT02478866Phase 1Completed
- Sponsor
- Betta Pharmaceuticals
- Start
- Aug 2015
- Primary completion
- Jun 2017
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of BPI-9016M in solid tumor, sponsored by Betta Pharmaceuticals. Primary endpoint: Participants with Adverse Events at 24 months. Started Aug 2015; status: completed.
02
Drugs
BPI-9016M
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT02478866.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02478866.